LONDON (Reuters) – Two high-risk bets by GlaxoSmithKline on new ways to fight heart disease and cancer were dealt a double blow last year by dud clinical trials – but the company remains hopeful about both projects.
Chief Executive Andrew Witty said on Wednesday there were still “intriguing” opportunities for its heart drug darapladib and MAGE-A3 therapeutic cancer vaccine.
Feb 5 (Reuters) – A small Dutch company behind the Western
world’s first approved gene therapy priced its shares above the
expected range in a U.S. stock offering on Wednesday, showing
the current investor appetite for biotechnology.
Amsterdam-based uniQure said it would sell 5.4
million shares at an initial public offering price of $17.00
each, netting it $81.9 million after expenses. It had previously
indicated a price range of $13.00 to $15.00.
LONDON (Reuters) – GlaxoSmithKline has predicted a pick-up in sales growth to around 2 percent this year as productivity in its drug research labs improves and pressure on sales in China moderates following a damaging bribery scandal.
Britain’s biggest drugmaker also said on Wednesday that it would stay market leader in the respiratory medicine market – a category it has dominated since the launch of Ventolin in 1969 – despite generic threats to its top-selling Advair drug.